Objective: To compare the efficacy of recombinant FSH and urinary-derived hMG for ovarian stimulation during IVF.
Design: Retrospective analysis of data from IVF cycles conducted over 15 months.
Setting: University hospital IVF unit.
Patient(s): Three hundred twenty-four women undergoing their first to sixth IVF cycle.
Intervention(s): After pituitary down-regulation, patients received recombinant FSH or hMG, according to personal choice. After hCG administration, patients underwent oocyte retrieval, oocyte fertilization, and embryo transfer.
Main outcome measure(s): Implantation rate and clinical ongoing pregnancy rate per oocyte retrieval.
Result(s): Patients who chose recombinant FSH were slightly younger than those who chose hMG (34.1 vs. 35.1 years, respectively). Although more embryos were transferred in the hMG group (3.6 vs. 3.2), the ongoing pregnancy and implantation rates were significantly higher in the recombinant FSH group (ongoing pregnancy rate, 50.0% vs. 36.2%).
Conclusion(s): Recombinant FSH is more effective than hMG for ovarian stimulation in IVF cycles. This increased efficacy, which is achieved with fewer ampoules, is likely to offset the higher acquisition costs of recombinant FSH.